PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to
determine whom would benefit from chemotherapy prior to surgery. Also could be used as a
clinical marker to identify patients with breast cancer who do not benefit from some
preoperative chemotherapies.
Phase:
Phase 2
Details
Lead Sponsor:
Angel Augusto Rodriguez, MD Jenny C. Chang, MD
Collaborators:
GE Healthcare The Methodist Hospital Research Institute The Methodist Hospital System